Hemostasis disorders caused by polymer coated iron oxide nanoparticles. 2013

Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
instituto de Ciencia de Materiales de Aragón, CSIC - Universidad de Zaragoza, and Departamento de Física de la Materia Condensada, Facultad de Ciencias, 50009 Zaragoza, Spain.

BACKGROUND Superparamagnetic iron oxide nanoparticles (SPIONs) are inorganic nanomaterials gaining strong clinical interest due to their increasing number of biological and medical applications. The stabilization of SPIONs in a biocompatible stable suspension (bioferrofluid) is generally achieved by an adequate polymeric coating. As many applications using these materials are intended for clinical use through intravenous injection, it is of outmost importance to evaluate their hemostatic behaviour. OBJECTIVE The aim of this work is to evaluate the hemocompatibility of selected polymer coated bioferrofluids and of their separated components by observing the effects of the bioferrofluid on: the coagulation process--by measuring the prothrombin time (PT) and activated partial thromboplastin time (aPTT)--, the complete blood count (CBC)--Erythrocytes, Leucocytes, Platelets, Hemoglobin and hematocrit--and the hemolysis. METHODS A SPIONs/bioferrofluid model consisting of a magnetic core of iron oxide nanoparticles embedded within poly(4-vinyl pyridine) (P4VP) and all coated with polyethylene glycol (PEG) has been selected. CONCLUSIONS By increasing the concentration of the bioferrofluids an inhibitory effect on the intrinsic pathway of blood coagulation is observed, as indicated by significant increase in aPTT in vitro while PT values stay normal. The effect of the coating components on the inhibition of blood coagulation process shows that PEG has no effect on the process while the P4VP-g-PEG copolymer coating has a strong anticoagulant effect indicating that P4VP is at the origin of such effects. The studied bioferrofluids have no effect on the CBC neither they show in vitro hemolytic effect on blood.

UI MeSH Term Description Entries
D008422 Materials Testing The testing of materials and devices, especially those used for PROSTHESES AND IMPLANTS; SUTURES; TISSUE ADHESIVES; etc., for hardness, strength, durability, safety, efficacy, and biocompatibility. Biocompatibility Testing,Biocompatible Materials Testing,Hemocompatibility Testing,Testing, Biocompatible Materials,Testing, Hemocompatible Materials,Hemocompatibility Testings,Hemocompatible Materials Testing,Materials Testing, Biocompatible,Materials Testing, Hemocompatible,Testing, Biocompatibility,Testing, Hemocompatibility,Testing, Materials,Testings, Biocompatibility
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D003911 Dextrans A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagulants. They are also commonly used in biological experimentation and in industry for a wide variety of purposes. Dextran,Dextran 40,Dextran 40000,Dextran 70,Dextran 75,Dextran 80,Dextran B-1355,Dextran B-1355-S,Dextran B1355,Dextran B512,Dextran Derivatives,Dextran M 70,Dextran T 70,Dextran T-40,Dextran T-500,Hemodex,Hyskon,Infukoll,Macrodex,Polyglucin,Promit,Rheodextran,Rheoisodex,Rheomacrodex,Rheopolyglucin,Rondex,Saviosol,Dextran B 1355,Dextran B 1355 S,Dextran T 40,Dextran T 500
D058185 Magnetite Nanoparticles Synthesized magnetic particles under 100 nanometers used in many biomedical applications including DRUG DELIVERY SYSTEMS and CONTRAST AGENTS. The particles are usually coated with a variety of polymeric compounds. Magnetite SPIONs,Magnetite Superparamagnetic Iron Oxide Nanoparticles,Superparamagnetic Magnetite Nanoparticles,Magnetite Nanoparticle,Magnetite Nanoparticle, Superparamagnetic,Magnetite Nanoparticles, Superparamagnetic,Magnetite SPION,Nanoparticle, Magnetite,Nanoparticle, Superparamagnetic Magnetite,Nanoparticles, Magnetite,Nanoparticles, Superparamagnetic Magnetite,SPION, Magnetite,SPIONs, Magnetite,Superparamagnetic Magnetite Nanoparticle
D020099 Coated Materials, Biocompatible Biocompatible materials usually used in dental and bone implants that enhance biologic fixation, thereby increasing the bond strength between the coated material and bone, and minimize possible biological effects that may result from the implant itself. Surface-Coated Materials,Biocompatible Coated Materials,Materials, Biocompatible Coated,Materials, Surface-Coated,Surface Coated Materials
D020141 Hemostatic Disorders Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS. Vascular Hemostatic Disorders,Hemostatic Disorders, Vascular,Disorder, Vascular Hemostatic,Disorders, Vascular Hemostatic,Hemostatic Disorder,Hemostatic Disorder, Vascular,Vascular Hemostatic Disorder

Related Publications

Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
May 2013, Biomaterials,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
January 2007, Journal of biomedicine & biotechnology,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
May 2014, International journal of pharmaceutics,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
January 2017, Methods in enzymology,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
January 2021, Current radiopharmaceuticals,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
August 2016, Recent patents on biotechnology,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
January 2016, Recent patents on biotechnology,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
January 2012, PloS one,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
September 2020, ACS applied materials & interfaces,
Lamiaa M A Ali, and Martín Gutiérrez, and Rosa Cornudella, and José Antonio Moreno, and Rafael Piñol, and Lierni Gabilondo, and Angel Millán, and Fernando Palacio
January 2009, Angewandte Chemie (International ed. in English),
Copied contents to your clipboard!